Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 3041-3048

  Larsen, Signe Benzon ^a   Brasso, Klaus ^b   Iversen, Peter ^b   Christensen, Jane ^a   Christiansen, Michael ^c   Carlsson, Sigrid ^d,e   Lilja, Hans ^d,f,g,h   Friis, Søren ^a   Tjønneland, Anne ^a   Dalton, Susanne Oksbjerg ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Urology Research Unit   (Denmark)

^c STATENS SERUM INSTITUT   (Denmark)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Baseline; Nested case control study; Prostate neoplasm; Prostate specific antigen; Risk factor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

BASELINE; NESTED CASE-CONTROL STUDY; PROSTATE NEOPLASM; PROSTATE-SPECIFIC ANTIGEN; RISK FACTOR;

AGED; CASE-CONTROL STUDIES; COHORT STUDIES; DENMARK; DIET; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84883049851     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.015     Document Type: Article

References (30)

1. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter N Engl J Med 350 22 2004 2239 2246
2. M.M. Center, A. Jemal, and J. Lortet-Tieulent International variation in prostate cancer incidence and mortality rates Eur Urol 61 6 2012 1079 1092
3. R. Etzioni, A. Tsodikov, and A. Mariotto Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19 2 2008 175 181
4. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 11 2012 981 990
5. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 8 2010 725 732
6. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 13 2009 1320 1328
7. M.J. Barry Screening for prostate cancer - the controversy that refuses to die N Engl J Med 360 13 2009 1351 1354
8. G.L. Andriole, R.L. Grubb III, and S.S. Buys Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 13 2009 1310 1319
9. R. Etzioni, D.F. Penson, and J.M. Legler Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 13 2002 981 990
10. G. Draisma, R. Boer, and S.J. Otto Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer J Natl Cancer Inst 95 12 2003 868 878
11. H.B. Carter, J.D. Pearson, and E.J. Metter Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 16 1992 2215 2220
12. H. Lilja, A.M. Cronin, and A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 6 2010 1210 1219
13. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
14. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 4 2007 431 436
15. D.D. Orsted, B.G. Nordestgaard, G.B. Jensen, P. Schnohr, and S.E. Bojesen Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population Eur Urol 61 5 2011 865 874
16. J. Fang, E.J. Metter, and P. Landis Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging Urology 58 3 2001 411 416
17. S. Loeb, H.B. Carter, W.J. Catalona, J.W. Moul, and F.H. Schroder Baseline prostate-specific antigen testing at a young age Eur Urol 61 1 2012 1 7
18. A.J. Vickers, M.J. Roobol, and H. Lilja Screening for prostate cancer: early detection or overdetection? Annu Rev Med 63 2012 161 170
19. M. Yin, S. Bastacky, U. Chandran, M.J. Becich, and R. Dhir Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors J Urol 179 3 2008 892 895
20. G.P. Haas, N.B. Delongchamps, and R.F. Jones Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence J Natl Cancer Inst 99 19 2007 1484 1489
21. A. Tjonneland, A. Olsen, and K. Boll Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population-based prospective cohort study of 57,053 men and women in Denmark Scand J Public Health 35 4 2007 432 441
22. M.L. Gjerstorff The Danish cancer registry Scand J Public Health 39 7 Suppl. 2011 42 45
23. R.L. Prentice, and N.E. Breslow Retrospective studies and failure time models Biometrika 65 1 1978 153 158
24. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.1. Association of the Nordic Cancer Registries. Danish Cancer Society. Available from http://www.ancr.nu, accessed on 1/9/2012.
25. Danish Urological Cancer Group. Prostate cancer guidelines 2011.
26. M. Outzen, K. Brasso, and N. Martinussen Prostate cancer in Denmark 1978-2009 - trends in incidence and mortality Acta Oncol 52 4 2013 831 836
27. M. Borre Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome BJU Int 104 2 2009 205 208
28. J. Adolfsson, H. Garmo, and E. Varenhorst Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 Scand J Urol Nephrol 41 6 2007 456 477
29. S.B. Larsen, S.O. Dalton, and J. Schuz Mortality among participants and non-participants in a prospective cohort study Eur J Epidemiol 27 11 2012 837 845
30. D. Ulmert, C. Becker, and J.A. Nilsson Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C Clin Chem 52 2 2006 235 239